Core Insights - Turn Therapeutics has appointed Dr. Kent E. Kester to its Board of Directors, enhancing its leadership in clinical and scientific domains at a crucial growth phase [1][3] Company Overview - Turn Therapeutics is a clinical-stage biotechnology company focused on developing next-generation therapies for dermatology, wound care, and infectious diseases [1][7] - The company has received three FDA clearances for its proprietary formulations and is advancing late-stage clinical programs in eczema and onychomycosis [7] Leadership Experience - Dr. Kester is a globally recognized infectious disease physician with over two decades of leadership experience in government, industry, and academia [2][4] - He has held senior roles, including Commander of the Walter Reed Army Institute of Research, and has led multi-center clinical programs from Phase 1 through pivotal studies [2][5] Strategic Importance - The appointment of Dr. Kester is expected to strengthen governance, sharpen strategy, and ensure a focus on patient impact and long-term value creation for Turn Therapeutics [3] - Dr. Kester's expertise in drug development and infectious disease is seen as invaluable for advancing the company's late-stage programs and approaching key regulatory milestones [3] Commitment to Public Health - Turn Therapeutics is pursuing global health initiatives, including thermostable vaccine delivery aimed at underserved areas, reflecting its commitment to public health innovation [7]

Core Insights - The healthcare sector has emerged as the best performing S&P 500 sector in October, reversing its previous lagging position [1] - The Health Care Select Sector SPDR ETF (XLV) has gained nearly 4.5% this quarter, while the broader S&P 500 remains largely flat [1] - XLV has attracted approximately $872 million in net new money by October 13, making it one of the top 10 equity ETF asset gatherers this quarter [1] Sector Performance - Prior to October, healthcare had experienced outflows of 6% of its start-of-the-year total assets, indicating a significant shift in investor sentiment [3] - The healthcare sector is characterized as defensive, less vulnerable to cyclical trends, and is currently trading at about a 27% discount to the S&P 500 [3][5] - State Street Investment Management projects XLV's 3-5 year earnings growth at 9.3%, compared to the S&P 500's forecast of 12% [3] Stock-Level Insights - Major healthcare stocks have performed well in October, with Eli Lilly up over 12%, Merck up 8%, Amgen up 7.5%, and Gilead up over 5% [5] - XLV, as the largest healthcare ETF with over $36 billion in assets, serves as a market-cap weighted proxy for the sector [6] Future Outlook - The healthcare sector's unique combination of valuation, growth potential, and defensive characteristics may continue to attract investor interest, especially amid macroeconomic uncertainties [7]

Investment Performance Summary - The Large Cap Composite (Gross) achieved a quarterly return of 4.7% and a year-to-date return of 10.0% [3][10] - The Small Cap Composite (Gross) reported a quarterly return of 4.3% and a year-to-date return of 6.6% [16] - The Focus Composite (Gross) had a quarterly return of 3.8% and a year-to-date return of 7.3% [20] - The All Cap Composite (Gross) recorded a quarterly return of 5.7% and a year-to-date return of 9.9% [29] Company Contributions and Detractors - Medpace Holdings Inc. was a significant contributor to performance, with revenue growing at a mid-teens rate and operating earnings up 20% year-over-year [13][33] - Alphabet Inc. also contributed positively, benefiting from a favorable remedies decision in an antitrust case [14][34] - CarMax Inc. was identified as a material detractor, experiencing a 5% decline in retail volumes due to market volatility [15][19] Strategic Actions - Fiserv Inc. was purchased during the quarter, expected to generate over $5 billion in free cash flow, which will be used for share repurchases [11][31] - CBRE Group Inc. was sold to reallocate capital to more discounted businesses, despite its strong market position [12][32] - No new positions were added in the Small Cap and Focus strategies during the quarter [17][21] Market Conditions and Outlook - Stock price volatility was noted earlier in the year due to tariff-related concerns, leading to capital allocation towards stable value companies [8] - The overall market is perceived as not cheap, but the portfolios maintain a margin of safety with attractive price-to-value ratios [9][10] - The used car market remains volatile, but CarMax is expected to leverage its competitive advantages for long-term growth [15][19]

Core Insights - Astria Therapeutics, Inc. (NASDAQ: ATXS) is a small biotech company with shares trading in the mid-$8 range, which has recently gained attention in the market [1] Company Overview - Astria Therapeutics is positioned within the biotechnology sector, focusing on innovative drug development [1] - The company is involved in creating unique therapies that may reshape treatment paradigms through novel mechanisms of action and first-in-class therapies [1] Analyst Background - The analyst has a Master's degree in Cell Biology and extensive experience in drug discovery, which informs their investment analysis [1] - The analyst has been active in the investing space for five years, with a focus on biotech equity analysis for the last four years [1] Investment Approach - The investment strategy emphasizes evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and potential market opportunities [1] - The goal is to provide research that is both technically sound and investment-driven, helping investors understand opportunities and risks in the biotech sector [1]

Group 1 - Adherex Technologies (FENC) is a clinical-stage biotechnology company focused on developing Sodium Thiosulfate to prevent ototoxicity from cisplatin in pediatric patients [1] - The Zacks Consensus Estimate for Adherex Technologies' current year earnings has been revised downward by approximately 55.6% over the last 60 days [1] Group 2 - Alibaba (BABA) is a leading e-commerce giant in China [2] - The Zacks Consensus Estimate for Alibaba's current year earnings has been revised downward by nearly 16.8% over the last 60 days [2] Group 3 - Alico (ALCO) is involved in various operations including citrus fruit production, cattle ranching, sugarcane and sod production, and forestry [2] - The Zacks Consensus Estimate for Alico's current year earnings has been revised downward by 5.8% over the last 60 days [2]

Colossal Biosciences, a $10 billion biotech, says, working with a group of scientists, it could create a new northern white rhino within four years https://t.co/NV56VXBsLH ...

Core Insights - The article discusses the author's transition to independent investment research after over 43 years in the industry, emphasizing a focus on actionable investment insights rather than adhering to external agendas [1] - The author highlights a unique approach to equity investing, combining quantitative analysis with fundamental theories to derive meaningful investment stories [1] - The article reflects on the author's extensive experience across various market segments and investment strategies, including managing a high-yield fixed-income fund and developing quantitative asset allocation strategies [1] Group 1 - The author has specialized in rules/factor-based equity investing strategies, aiming to use numbers to inspire human intelligence-driven investment narratives [1] - The author critiques traditional quantitative investing methods, advocating for a blend of factor analysis and classic fundamental analysis to understand a company's future potential [1] - The author has a diverse background, covering a wide range of stocks and investment types, including large cap, small cap, micro cap, value, growth, and income [1] Group 2 - The author has previously managed a high-yield fixed-income fund and has experience in quantitative asset allocation strategies, which are foundational to modern Robo Advising [1] - The author has authored two books on investment strategies and has conducted numerous seminars focused on stock selection and analysis [1] - The article expresses enthusiasm for the author's new role on Seeking Alpha, inviting feedback and engagement from the audience [1]

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, aimed at both novice and experienced investors [1] - The newsletter provides insights on key trends, catalysts driving valuations, product sales forecasts, and integrated financial statements for major pharmaceutical companies [1] - The author, Edmund Ingham, has over five years of experience in biotech consulting and has prepared detailed reports on more than 1,000 companies [1]

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, aimed at both novice and experienced investors [1] - The newsletter provides insights on key trends, catalysts driving valuations, product sales forecasts, and integrated financial statements for major pharmaceutical companies [1] - The author, Edmund Ingham, has over five years of experience in biotech consulting and has prepared detailed reports on more than 1,000 companies [1]

Core Insights - Century Therapeutics, Inc. is focused on developing induced pluripotent stem cell (iPSC)-derived cell therapies targeting autoimmune diseases and cancer [1][3] - Chad Cowan, Ph.D., the Chief Scientific Officer, will present at Chardan's 9th Annual Genetic Medicines Conference on October 21, 2025 [1] - The company utilizes its proprietary Allo-Evasion™ technology to enhance immune evasion in its therapies, aiming to improve patient access and treatment outcomes [3] Company Overview - Century Therapeutics is a clinical-stage biotechnology firm listed on NASDAQ under the ticker IPSC [3] - The company is advancing a pipeline of iPSC-derived cell therapies, which are designed to address significant medical needs in autoimmune diseases and cancer [3] - The therapies are produced from the company's iPSC cell foundry, indicating a focus on innovative and scalable treatment solutions [3] Presentation Details - The presentation by Chad Cowan will take place at 12:20 p.m. ET in New York, NY [1] - A live webcast of the presentation will be accessible on the company's Investors page, with an archived replay available for at least 30 days [2]